Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: IJH VTI VB VBK VXF XBI MDY IBB IWP IJK

Index	-	P/E	36.96	EPS (ttm)	4.19	Insider Own	2.64%	Shs Outstand	99.70M	Perf Week	0.34%
Market Cap	15.43B	Forward P/E	21.86	EPS next Y	7.08	Insider Trans	-8.53%	Shs Float	97.07M	Perf Month	5.06%
Enterprise Value	14.79B	PEG	0.61	EPS next Q	1.86	Inst Own	98.34%	Short Float	4.11%	Perf Quarter	9.08%
Income	428.00M	P/S	5.75	EPS this Y	55.34%	Inst Trans	-1.25%	Short Ratio	4.16	Perf Half Y	23.79%
Sales	2.68B	P/B	5.14	EPS next Y	38.54%	ROA	10.97%	Short Interest	3.99M	Perf YTD	13.37%
Book/sh	30.13	P/C	13.84	EPS next 5Y	36.00%	ROE	14.96%	52W High	160.18 -3.39%	Perf Year	19.85%
Cash/sh	11.18	P/FCF	26.01	EPS past 3/5Y	53.21% 53.47%	ROIC	12.47%	52W Low	84.23 83.72%	Perf 3Y	28.73%
Dividend Est.	-	EV/EBITDA	25.36	Sales past 3/5Y	27.61% 24.48%	Gross Margin	98.14%	Volatility	2.75% 2.84%	Perf 5Y	60.31%
Dividend TTM	-	EV/Sales	5.51	EPS Y/Y TTM	11.36%	Oper. Margin	20.64%	ATR (14)	4.43	Perf 10Y	203.55%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	19.61%	Profit Margin	15.95%	RSI (14)	62.77	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.38	EPS Q/Q	64.23%	SMA20	4.42%	Beta	0.28	Target Price	176.84
Payout	0.00%	Debt/Eq	0.16	Sales Q/Q	27.78%	SMA50	6.91%	Rel Volume	0.98	Prev Close	155.63
Employees	1800	LT Debt/Eq	0.14	Earnings	Oct 28 AMC	SMA200	20.22%	Avg Volume	958.08K	Price	154.75
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	27.95% 6.43%	Trades		Volume	940,403	Change	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130

Show Previous Ratings

Dec-09-25 04:01PM	Neurocrine Biosciences to Host R&D Day on December 16 (PR Newswire)
Dec-05-25 08:03AM	Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level (Investor's Business Daily)
Nov-27-25 12:45PM	Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily) +5.61%
Nov-20-25 08:30AM	Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules (PR Newswire)
04:01PM	Loading…
Nov-11-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (Zacks)
Nov-10-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
01:25PM	Neurocrine chalks up a depression drug failure (BioPharma Dive)
Nov-06-25 12:20PM	Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? (Zacks)
Nov-04-25 12:00PM	What Makes Neurocrine (NBIX) a New Strong Buy Stock (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Loading…
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)
07:30PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter (Investor's Business Daily)
04:19PM	Neurocrine Bio Surges After Crushing Third-Quarter Expectations (Investor's Business Daily)
04:06PM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-24-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
Oct-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) (Zacks)
Oct-22-25 05:15PM	USANA Health Sciences (USNA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules (PR Newswire)
04:01PM	Loading…
Oct-07-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
Oct-06-25 04:05PM	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Sep-25-25 09:55AM	Should You be Optimistic on Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-24-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Sep-23-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden (PR Newswire)
Sep-22-25 08:30AM	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
Sep-16-25 04:05PM	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
02:58PM	What Does Wall Street Think About Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-02-25 04:03AM	Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access (Insider Monkey)
Aug-26-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-20-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-06-25 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-31-25 03:32AM	Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -6.24%
Jul-30-25 06:00PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:05PM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 11:40AM	CPRX vs. NBIX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-27-25 09:58AM	Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence (Insider Monkey)
Jul-25-25 11:28PM	Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating (Insider Monkey)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-15-25 10:57AM	Neurocrine shares new one-year data from trial of Crenessity for CAH (Clinical Trials Arena)
09:00AM	Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Analysis of CAHtalog Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 (PR Newswire)
Jul-14-25 04:35PM	Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting (PR Newswire)
08:30AM	Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY (crinecerfont) in Adult Patients, at ENDO 2025 (PR Newswire)
Jul-10-25 11:26PM	Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List (Insider Monkey)
08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-09-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results (PR Newswire)
Jun-30-25 04:05PM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist (PR Newswire)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Jun-23-25 11:40AM	EGO or AEM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 08:30AM	Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia (PR Newswire)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-09-25 04:05PM	Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer (PR Newswire)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-02-25 08:30AM	Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGREZZA (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia (PR Newswire)
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire)
May-29-25 12:03AM	Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched (Insider Monkey)
May-28-25 04:05PM	Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (PR Newswire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
May-26-25 06:20AM	Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now? (Zacks)
May-20-25 06:20AM	Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? (Zacks)
May-16-25 08:30AM	Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting (PR Newswire)
08:25AM	Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia (PR Newswire)
May-15-25 04:05PM	Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY (crinecerfont) (PR Newswire)
11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
May-14-25 04:05PM	Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia (PR Newswire)
May-13-25 03:48PM	Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin's Midcap Stock Picks with Huge Upside Potential (Insider Monkey)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
06:20AM	Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar? (Zacks)
May-08-25 08:30AM	Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst Pediatric Study Demonstrating CRENESSITY Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups (PR Newswire)
May-07-25 03:34AM	Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday (Insider Monkey)
May-06-25 04:40PM	Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug (Investor's Business Daily) +8.36%
04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in May (PR Newswire)
08:36AM	Q1 2025 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:30AM	Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie Awareness Campaign for People with Tardive Dyskinesia (PR Newswire)
06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks)
03:05AM	Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... (GuruFocus.com)
May-05-25 08:33PM	Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks)
04:09PM	Neurocrine: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance (PR Newswire)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Option Exercise	43.24	4,376	189,218	47,781	Dec 10 09:04 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Sale	159.65	4,376	698,615	43,405	Dec 10 09:04 AM
DARIN LIPPOLDT	Officer	Dec 08 '25	Proposed Sale	155.51	4,376	680,512		Dec 08 04:35 PM
LYONS GARY A	Director	Dec 03 '25	Option Exercise	47.89	15,000	718,350	135,482	Dec 04 04:14 PM
LYONS GARY A	Director	Dec 03 '25	Sale	152.61	15,000	2,289,082	120,482	Dec 04 04:14 PM
GARY A LYONS REVOCABLE LIVING	Director	Dec 03 '25	Proposed Sale	152.48	15,000	2,287,200		Dec 03 04:36 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Option Exercise	35.99	5,970	214,860	50,863	Dec 02 05:21 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Sale	151.74	5,970	905,881	44,893	Dec 02 05:21 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '25	Option Exercise	0.00	4,426	0	18,129	Dec 02 05:14 PM
ERIC BENEVICH	Officer	Nov 28 '25	Proposed Sale	151.58	5,970	904,933		Nov 28 01:20 PM
MORROW GEORGE J	Director	Nov 25 '25	Option Exercise	47.89	15,000	718,350	22,068	Nov 26 04:28 PM
MORROW GEORGE J	Director	Nov 25 '25	Sale	143.37	15,000	2,150,512	7,068	Nov 26 04:28 PM
GEORGE MORROW	Director	Nov 25 '25	Proposed Sale	141.25	15,000	2,118,750		Nov 25 04:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Option Exercise	47.89	18,000	862,020	58,360	Nov 06 05:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Sale	151.82	18,000	2,732,690	40,360	Nov 06 05:25 PM
Gano Kyle	Officer	Nov 04 '25	Proposed Sale	141.97	300	42,591		Nov 05 09:09 PM
WILLIAM H. RASTETTER	Director	Nov 05 '25	Proposed Sale	143.19	18,000	2,577,420		Nov 05 04:19 PM
Gano Kyle	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	613	0	140,720	Nov 04 08:18 PM
Gano Kyle	Chief Executive Officer	Nov 04 '25	Sale	141.97	300	42,591	140,407	Nov 04 08:18 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Option Exercise	35.99	106,322	3,826,529	620,918	Aug 11 04:55 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Sale	126.41	106,322	13,440,281	514,596	Aug 11 04:55 PM
KEVIN CHARLES GORMAN	Director	Aug 07 '25	Proposed Sale	128.43	106,322	13,654,934		Aug 07 04:24 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM
RASTETTER WILLIAM H	Director	May 05 '25	Option Exercise	42.76	30,000	1,282,800	67,491	May 07 07:05 PM
RASTETTER WILLIAM H	Director	May 05 '25	Sale	110.20	30,000	3,305,952	37,491	May 07 07:05 PM
WILLIAM H. RASTETTER	Officer	May 05 '25	Proposed Sale	109.68	30,000	3,290,400		May 05 04:40 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Option Exercise	0.00	2,910	0	20,945	Feb 14 07:13 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Sale	116.78	1,551	181,129	19,544	Feb 14 07:13 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Option Exercise	0.00	10,979	0	527,221	Feb 14 06:57 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Sale	116.69	5,844	681,914	521,618	Feb 14 06:57 PM
SHERWIN STEPHEN A	Director	Feb 13 '25	Sale	116.69	13,831	1,613,923	10,673	Feb 14 06:49 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Option Exercise	0.00	4,605	0	36,140	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Sale	116.85	1,718	200,742	34,252	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 14 '25	Sale	115.04	500	57,521	35,640	Feb 14 06:42 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Option Exercise	0.00	5,407	0	19,536	Feb 14 06:35 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Sale	116.79	2,879	336,239	16,846	Feb 14 06:35 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Option Exercise	0.00	4,100	0	44,491	Feb 14 06:26 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Sale	116.75	2,184	254,992	42,474	Feb 14 06:26 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	141,113	Feb 14 06:20 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Sale	116.85	2,558	298,908	138,872	Feb 14 06:20 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Option Exercise	0.00	2,759	0	5,485	Feb 14 06:13 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Sale	116.71	1,471	171,674	4,084	Feb 14 06:13 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Option Exercise	0.00	3,352	0	4,395	Feb 14 06:08 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Sale	116.74	1,785	208,387	2,854	Feb 14 06:08 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Option Exercise	0.00	4,044	0	45,745	Feb 14 06:03 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Sale	116.73	2,154	251,428	43,784	Feb 14 06:03 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	37,016	Feb 14 06:00 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Sale	116.86	2,558	298,923	34,775	Feb 14 06:00 PM
EIRY WYN ROBERTS	Officer	Feb 14 '25	Proposed Sale	115.04	500	57,521		Feb 14 04:12 PM
STEPHEN A SHERWIN	Director	Feb 13 '25	Proposed Sale	117.18	13,831	1,620,717		Feb 13 04:38 PM
MATTHEW ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:38 PM
MATTHEW C ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
KEVIN CHARLES GORMAN	Director	Feb 13 '25	Proposed Sale	117.18	3,012	352,946		Feb 13 04:37 PM
KYLE W GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
JULIE SMITH COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:37 PM
ERIC S BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,056	123,742		Feb 13 04:36 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,447	169,559		Feb 13 04:36 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:36 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	830	97,259		Feb 13 04:35 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,086	127,257		Feb 13 04:35 PM
EIRY WYN ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	604	70,777		Feb 13 04:35 PM
EIRY ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	1,114	130,539		Feb 13 04:34 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
ERIC BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,432	167,802		Feb 13 04:34 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	716	83,901		Feb 13 04:33 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	955	111,907		Feb 13 04:33 PM
JULIE COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	796	93,275		Feb 13 04:33 PM
KYLE GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:32 PM
Kevin Charles Gorman	Director	Feb 13 '25	Proposed Sale	117.18	2,832	331,854		Feb 13 04:31 PM
Cooke Julie	Chief Human Resources Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	19,531	Feb 12 07:00 PM
Cooke Julie	Chief Human Resources Officer	Feb 10 '25	Sale	118.28	700	82,792	18,831	Feb 12 07:00 PM
GORMAN KEVIN CHARLES	Director	Feb 08 '25	Option Exercise	0.00	4,318	0	521,348	Feb 12 06:56 PM
GORMAN KEVIN CHARLES	Director	Feb 10 '25	Sale	118.37	2,274	269,167	519,074	Feb 12 06:56 PM
ROBERTS EIRY	Chief Medical Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	34,233	Feb 12 06:52 PM
ROBERTS EIRY	Chief Medical Officer	Feb 10 '25	Sale	118.22	980	115,853	33,253	Feb 12 06:52 PM
Lippoldt Darin	Chief Legal Officer	Feb 08 '25	Option Exercise	0.00	1,727	0	42,590	Feb 12 06:49 PM
Lippoldt Darin	Chief Legal Officer	Feb 10 '25	Sale	118.25	911	107,727	41,679	Feb 12 06:49 PM
Gano Kyle	Chief Executive Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	138,638	Feb 12 06:48 PM
Gano Kyle	Chief Executive Officer	Feb 10 '25	Sale	118.39	980	116,020	137,658	Feb 12 06:48 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	2,698	Feb 12 06:46 PM

Open in Screener

TVTX

Travere Therapeutics Inc

Dec 11 • 04:00PM ET

35.01

+0.63 1.83 %

Healthcare • Biotechnology • USA • NASD

TVTX Travere Therapeutics Inc daily Stock Chart

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT PJP

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	1.95%	Shs Outstand	89.46M	Perf Week	-0.91%
Market Cap	3.13B	Forward P/E	42.26	EPS next Y	0.83	Insider Trans	-12.32%	Shs Float	87.73M	Perf Month	-3.05%
Enterprise Value	3.21B	PEG	-	EPS next Q	-0.07	Inst Own	116.69%	Short Float	12.50%	Perf Quarter	49.17%
Income	-88.54M	P/S	7.19	EPS this Y	90.13%	Inst Trans	-3.49%	Short Ratio	5.69	Perf Half Y	134.34%
Sales	435.83M	P/B	42.57	EPS next Y	305.79%	ROA	-16.98%	Short Interest	10.97M	Perf YTD	100.98%
Book/sh	0.82	P/C	12.31	EPS next 5Y	-	ROE	-410.78%	52W High	37.50 -6.64%	Perf Year	86.52%
Cash/sh	2.84	P/FCF	-	EPS past 3/5Y	-10.63% -3.34%	ROIC	-22.27%	52W Low	12.91 171.19%	Perf 3Y	74.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.83% 5.87%	Gross Margin	85.08%	Volatility	4.23% 4.65%	Perf 5Y	39.54%
Dividend TTM	-	EV/Sales	7.36	EPS Y/Y TTM	77.02%	Oper. Margin	-20.59%	ATR (14)	1.60	Perf 10Y	60.30%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	114.22%	Profit Margin	-20.32%	RSI (14)	56.16	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	2.75	EPS Q/Q	135.55%	SMA20	-0.07%	Beta	0.86	Target Price	41.50
Payout	-	Debt/Eq	4.48	Sales Q/Q	162.11%	SMA50	10.70%	Rel Volume	0.78	Prev Close	34.38
Employees	385	LT Debt/Eq	4.40	Earnings	Oct 30 AMC	SMA200	63.10%	Avg Volume	1.93M	Price	35.01
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	192.20% 56.70%	Trades		Volume	1,508,932	Change	1.83%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22

Show Previous Ratings

Today 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-25 08:00AM	Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
Nov-10-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31% +5.03%
Nov-06-25 11:00AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Nov-04-25 05:23PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
01:34AM	Loading…
Nov-03-25 01:34AM	Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings (Insider Monkey)
Nov-01-25 02:48PM	Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook (Insider Monkey)
Oct-31-25 07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks) +18.58%
04:06PM	Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat (Investor's Business Daily)
Oct-30-25 11:02PM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Highlights: Strong FILSPARI Sales and ... (GuruFocus.com)
06:30PM	Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:51PM	Travere: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-29-25 09:41AM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
06:58AM	Loading…
Oct-27-25 06:58AM	Chugai acquires Renalys, enhancing its kidney disease portfolio (Pharmaceutical Technology) +6.09%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-23-25 04:30PM	Travere Therapeutics to Report Third Quarter 2025 Financial Results (Business Wire)
12:22PM	Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling (Investor's Business Daily)
Oct-17-25 09:01AM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 12:00PM	What Makes Travere (TVTX) a New Strong Buy Stock (Zacks)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 05:11PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-25 07:00AM	CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy (Business Wire)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 01:16PM	Hims & Hers Leads 14 Growth Stocks Amid Medical Boom (Investor's Business Daily) -6.12%
Sep-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.46%
10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
09:15AM	Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside (Insider Monkey)
04:57AM	Loading…
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 11:17AM	Stock Market Today: Inflation Data Hits Dow; Oracle Soars As This Biotech Zooms (Live Coverage) (Investor's Business Daily) +26.20%
09:13AM	Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High (Investor's Business Daily)
07:01AM	Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI (sparsentan) in FSGS (Business Wire)
Sep-03-25 07:01AM	Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism (Business Wire) +8.04%
Aug-28-25 10:00AM	Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch (Investor's Business Daily)
Aug-27-25 05:09PM	Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI (sparsentan) in IgA Nephropathy (Business Wire)
Aug-17-25 11:41PM	Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts (Insider Monkey)
Aug-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 09:06AM	Travere Therapeutics price target raised to $32 from $30 at Wedbush (TipRanks)
Aug-06-25 06:00PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Travere: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
09:54AM	Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 04:30PM	Travere Therapeutics to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-06-25 04:15AM	Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) (Insider Monkey)
Jun-24-25 12:46PM	Travere Therapeutics Kicks Off "Play It Forward" Campaign for FSGS Awareness (Insider Monkey) +5.18%
Jun-13-25 02:02PM	HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs (Insider Monkey)
Jun-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:01AM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the 15th International Podocyte Conference (Business Wire)
Jun-10-25 07:00AM	Travere Therapeutics Launches 'Play It Forward' Campaign to Celebrate the FSGS Community on Inaugural Awareness Day (Business Wire)
Jun-03-25 04:30PM	Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress (Business Wire)
May-23-25 04:00AM	England's NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy (PR Newswire)
May-15-25 04:05PM	Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire) -20.57%
May-13-25 04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.59%
May-07-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
May-01-25 11:07PM	Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Travere Therapeutics Reports First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 07:01AM	Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy (Business Wire)
02:00AM	CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy (PR Newswire)
Apr-28-25 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.62%
Apr-24-25 04:30PM	Travere Therapeutics to Report First Quarter 2025 Financial Results (Business Wire) +5.57%
Apr-12-25 10:20AM	Travere Therapeutics price target lowered to $30 from $32 at Scotiabank (TipRanks)
Apr-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.49%
Apr-07-25 03:27AM	Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-31-25 04:30PM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 (Business Wire) -8.94%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 09:39PM	Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire)
Mar-17-25 07:01AM	Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS (GlobeNewswire) +5.78%
Mar-12-25 05:30PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.32%
Feb-24-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-25 03:03PM	Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-22-25 09:20AM	Travere Therapeutics price target raised to $30 from $24 at TD Cowen (TipRanks)
Feb-20-25 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.79%
09:06AM	What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings (GuruFocus.com)
Feb-14-25 02:06PM	Travere Therapeutics (TVTX): Among The SmallCap Stocks Insiders Are Selling Recently (Insider Monkey)
Feb-13-25 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
10:31AM	Travere Therapeutics price target raised to $32 from $27 at Scotiabank (TipRanks)
Feb-12-25 05:30PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-25 07:01AM	Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS (GlobeNewswire) +12.56%
Jan-13-25 07:00AM	Travere Therapeutics Provides Corporate Update and 2025 Outlook (GlobeNewswire)
Jan-06-25 04:30PM	Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-03-24 05:51AM	Japan MHLW grants orphan drug status to Renalys' sparsentan for IgAN treatment (Pharmaceutical Business Review)
Nov-25-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-12-24 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Nov-07-24 09:05PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +12.40%
04:01PM	Travere Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-04-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 03:05AM	Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Option Exercise	16.23	20,000	324,600	112,083	Dec 03 04:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Sale	35.01	20,000	700,202	92,083	Dec 03 04:30 PM
CHRISTOPHER CLINE	Officer	Dec 01 '25	Proposed Sale	35.01	20,000	700,200		Dec 01 04:09 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Option Exercise	24.02	61,250	1,471,212	115,660	Nov 06 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Sale	36.00	67,115	2,416,140	48,545	Nov 06 04:05 PM
SANDRA CALVIN	Officer	Nov 04 '25	Proposed Sale	36.00	67,115	2,416,140		Nov 04 04:14 PM
Coughlin Timothy	Director	Oct 31 '25	Option Exercise	16.95	18,000	305,040	73,500	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Sale	35.03	18,000	630,601	55,500	Nov 04 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 31 '25	Sale	35.00	5,591	195,685	119,071	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Proposed Sale	34.98	18,000	629,693		Oct 31 04:05 PM
Heerma Peter	Officer	Oct 31 '25	Proposed Sale	35.00	5,591	195,685		Oct 31 02:51 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Option Exercise	15.46	92,872	1,435,801	512,045	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Option Exercise	15.46	27,128	419,399	446,301	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Sale	30.38	92,872	2,821,358	419,173	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Sale	30.12	27,128	817,074	419,173	Oct 30 04:45 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 28 '25	Sale	30.00	2,662	79,860	124,662	Oct 30 04:45 PM
Dube Eric M	Officer	Oct 29 '25	Proposed Sale	30.12	27,128	817,045		Oct 29 04:26 PM
Dube Eric M	Officer	Oct 28 '25	Proposed Sale	30.38	92,872	2,821,217		Oct 28 04:57 PM
Heerma Peter	Officer	Oct 28 '25	Proposed Sale	30.00	2,662	79,860		Oct 28 02:08 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Option Exercise	19.08	10,000	190,800	99,878	Sep 24 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Sale	25.00	10,000	250,000	89,878	Sep 24 04:05 PM
ELIZABETH REED	Officer	Sep 22 '25	Proposed Sale	25.00	10,000	250,000		Sep 22 04:02 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 03 '25	Sale	18.20	454	8,263	92,202	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 04 '25	Sale	19.71	119	2,345	92,083	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	17.31	470	8,136	92,656	Aug 28 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	14.65	815	11,940	88,787	Jul 02 05:28 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 05 '25	Sale	21.05	1,784	37,553	93,126	May 05 09:54 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 05 '25	Sale	21.05	18,924	398,350	419,173	May 05 09:53 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 05 '25	Sale	21.05	1,771	37,280	128,215	May 05 09:53 PM
ROTE WILLIAM E.	Chief Research Officer	May 05 '25	Sale	21.05	3,198	67,318	100,241	May 05 09:52 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 05 '25	Sale	21.05	4,920	103,566	89,482	May 05 09:51 PM
Christopher Cline	Officer	May 05 '25	Proposed Sale	21.05	1,784	37,553		May 05 07:45 PM
Peter Heerma	Officer	May 05 '25	Proposed Sale	21.05	1,771	37,280		May 05 07:41 PM
REED ELIZABETH E	Officer	May 05 '25	Proposed Sale	21.05	4,920	103,566		May 05 11:32 AM
Dube Eric M	Officer	May 05 '25	Proposed Sale	21.05	18,924	398,350		May 05 11:20 AM
ROTE WILLIAM E.	Officer	May 05 '25	Proposed Sale	21.05	3,198	67,318		May 05 10:08 AM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '25	Sale	13.14	48	631	89,990	Apr 14 06:23 PM
Christopher Cline	Officer	Apr 11 '25	Proposed Sale	13.14	48	631		Apr 11 07:03 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 12 '25	Sale	23.53	5,200	122,356	98,519	Feb 12 09:30 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 12 '25	Sale	23.53	8,000	188,240	89,482	Feb 12 09:28 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 11 '25	Option Exercise	16.63	45,000	748,200	78,654	Feb 12 09:27 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 11 '25	Sale	25.00	54,244	1,356,100	54,410	Feb 12 09:27 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 11 '25	Sale	25.00	3,074	76,850	127,634	Feb 12 09:25 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 12 '25	Sale	23.53	2,568	60,426	125,066	Feb 12 09:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 11 '25	Sale	24.04	11,375	273,455	419,173	Feb 12 09:23 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 12 '25	Sale	23.53	2,568	60,426	89,602	Feb 12 09:22 PM
Peter Heerma	Officer	Feb 12 '25	Proposed Sale	23.53	2,568	60,426		Feb 12 07:47 PM
Jula Inrig	Officer	Feb 12 '25	Proposed Sale	23.53	2,568	60,426		Feb 12 07:46 PM
ROTE WILLIAM E.	Officer	Feb 12 '25	Proposed Sale	23.53	5,200	122,356		Feb 12 11:03 AM
REED ELIZABETH E	Officer	Feb 12 '25	Proposed Sale	23.53	8,000	188,240		Feb 12 09:52 AM
SANDRA CALVIN	Officer	Feb 11 '25	Proposed Sale	25.00	54,244	1,356,100		Feb 11 04:08 PM
PETER HEERMA	Officer	Feb 11 '25	Proposed Sale	25.00	3,074	76,850		Feb 11 04:04 PM
Dube Eric M	Officer	Feb 11 '25	Proposed Sale	24.04	11,375	273,455		Feb 11 11:56 AM
Baynes Roy D.	Director	Feb 06 '25	Option Exercise	17.44	10,000	174,400	41,000	Feb 10 06:04 PM
Baynes Roy D.	Director	Feb 06 '25	Sale	22.00	10,000	220,000	31,000	Feb 10 06:04 PM
ROY D BAYNES	Director	Feb 06 '25	Proposed Sale	22.00	10,000	220,000		Feb 06 04:21 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 03 '25	Sale	19.78	8,951	177,051	95,719	Feb 04 08:30 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 03 '25	Sale	19.78	8,951	177,051	89,482	Feb 04 08:30 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 03 '25	Sale	20.21	50,691	1,024,343	430,548	Feb 04 08:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 03 '25	Sale	20.12	4,207	84,645	85,236	Feb 04 08:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 04 '25	Sale	20.11	1,066	21,437	84,170	Feb 04 08:30 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 03 '25	Sale	20.12	5,166	103,940	122,708	Feb 04 08:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 03 '25	Sale	20.12	5,192	104,463	90,038	Feb 04 08:30 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 03 '25	Sale	20.12	3,348	67,362	63,654	Feb 04 08:30 PM
JULA INRIG	Officer	Feb 04 '25	Proposed Sale	20.11	1,066	21,437		Feb 04 04:11 PM
Peter Heerma	Officer	Feb 03 '25	Proposed Sale	20.12	5,166	103,934		Feb 03 08:47 PM
Christopher Cline	Officer	Feb 03 '25	Proposed Sale	20.12	5,192	104,457		Feb 03 08:46 PM
Sandra Calvin	Officer	Feb 03 '25	Proposed Sale	20.12	3,348	67,358		Feb 03 08:41 PM
Jula Inrig	Officer	Feb 03 '25	Proposed Sale	20.12	4,207	84,640		Feb 03 08:40 PM
REED ELIZABETH E	Officer	Feb 03 '25	Proposed Sale	19.78	8,951	177,051		Feb 03 12:26 PM
Dube Eric M	Officer	Feb 03 '25	Proposed Sale	19.78	50,691	1,002,668		Feb 03 11:22 AM
ROTE WILLIAM E.	Officer	Feb 03 '25	Proposed Sale	19.78	8,951	177,051		Feb 03 11:11 AM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Jan 22 '25	Sale	19.46	2,437	47,424	83,170	Jan 23 08:40 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 22 '25	Sale	19.46	10,736	208,923	351,239	Jan 23 08:39 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Jan 22 '25	Sale	19.46	2,437	47,424	76,933	Jan 23 08:37 PM
Baynes Roy D.	Director	Jan 23 '25	Option Exercise	17.50	16,000	280,000	47,000	Jan 23 08:36 PM
Baynes Roy D.	Director	Jan 23 '25	Sale	20.00	16,000	320,000	31,000	Jan 23 08:36 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Jan 22 '25	Sale	18.94	1,584	30,002	106,374	Jan 23 08:35 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Jan 22 '25	Sale	18.94	865	16,384	73,730	Jan 23 08:33 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Jan 22 '25	Sale	18.94	925	17,520	54,002	Jan 23 08:31 PM
ROY D BAYNES	Director	Jan 23 '25	Proposed Sale	20.00	16,000	320,000		Jan 23 04:14 PM
Dube Eric M	Officer	Jan 22 '25	Proposed Sale	19.46	10,736	208,923		Jan 22 10:34 AM
REED ELIZABETH E	Officer	Jan 22 '25	Proposed Sale	19.46	2,437	47,424		Jan 22 10:18 AM
ROTE WILLIAM E.	Officer	Jan 22 '25	Proposed Sale	19.46	2,437	47,424		Jan 22 09:36 AM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 03 '25	Sale	19.10	2,066	39,461	59,883	Jan 06 07:21 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 06 '25	Sale	18.76	440	8,254	59,443	Jan 06 07:21 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 26 '24	Option Exercise	12.67	15,000	190,050	69,927	Dec 27 07:47 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 26 '24	Sale	17.22	15,000	258,277	54,927	Dec 27 07:47 PM
SANDRA CALVIN	Officer	Dec 26 '24	Proposed Sale	17.22	15,000	258,278		Dec 26 04:13 PM

NBIX

Neurocrine Biosciences, Inc

TVTX

Travere Therapeutics Inc

Upgrade your FINVIZ experience